Press Release

NeoGenomics Liquid Biopsy Subsidiary Inivata Announces New Data Demonstrating Clinical Potential of the RaDaR(TM) MRD Test in HR+ HER2- Breast Cancer

NeoGenomics Receives CAP Certification in their Suzhou China Pharma Services Laboratory

NeoGenomics To Participate In Multiple Upcoming Institutional Investor Conferences

NeoGenomics Appoints Lynn Tetrault Interim CEO

NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Present New Data Further Validating the Application of its RaDaR® MRD and InVisionFirst®-Lung Tests at the 2022 ASCO Annual Meeting

NeoGenomics Announces Leadership Transition Appointing Vishal Sikri as President and Chief Commercial Officer of Inivata Liquid Biopsy Subsidiary

NeoGenomics To Participate in the BofA Securities 2022 Healthcare Conference

NeoGenomics Reports Revenue of $117 Million in the First Quarter

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients